12651 High Bluff Drive
About Cirius Therapeutics
Cirius Therapeutics, a clinical-stage pharmaceutical company, is developing MSDC-0602K, a next-generation insulin sensitizer for the treatment of nonalcoholic steatohepatitis (NASH). MSDC-0602K is currently being evaluated in a Phase 2b clinical trial. Through its novel insulin sensitizing mechanism of action, MSDC-0602K has potential to resolve the underlying pathophysiology of NASH.
Founder: Jerry Colca
CEO: Bob Baltera
CMO: Howard Dittrich
CBO: Brian Farmer
Please click here for clinical trial information.
3 articles with Cirius Therapeutics
With headquarters located in San Diego, Calif. and Kalamazoo, Mich., Cirius Therapeutics is a clinical-stage pharmaceutical company focused on developing a treatment for NASH.
Cirius Therapeutics announced today that Dennis Fenton, Ph.D., has been appointed to the company's board of directors as an independent member.
BioSpace is proud to present its NextGen "Class of 2018," a list of 20 up-and-coming life science companies in North America that started up no earlier than 2015.